Use of human papillomavirus type 6 capsids to detect antibodies in people with genital warts.
Carter JJ,
Wipf GC,
Hagensee ME,
McKnight B,
Habel LA,
Lee SK,
Kuypers J,
Kiviat N,
Daling JR,
Koutsky LA, et al.
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA.
Human papillomavirus (HPV) type 6 capsids were produced by recombinant vaccinia viruses and used in a capture ELISA to screen 901 human sera from three studies of genital HPVs. The highest seroprevalence was observed among subjects with recurrent genital warts. In a population-based case-control study of genital warts, 26 (58%) of 45 women with recurrent genital warts were seropositive compared with 19 (19%) of 101 control women with no history of genital warts (odds ratio, 6.5; 95% confidence interval, 3.0, 14.1). Among a cohort of pregnant women, 7 (88%) of 8 with recurrent warts were seropositive compared with 24 (30%) of 79 pregnant women with no such history. A significant association between seropositivity to HPV-6 capsids and the detection of HPV-6/11 DNA from genital specimens by polymerase chain reaction was also observed. Men with genital warts were less likely to be seropositive than were women with genital warts, and a positive association between the number of sex partners and seropositivity was observed among only the female university students.
PMID: 7797899 [PubMed - indexed for MEDLINE]